CJC-1295 / Ipamorelin vs Sermorelin

CJC-1295 / Ipamorelin

The workhorse GH-secretagogue stack: a GHRH analogue paired with a selective ghrelin agonist. GHRH plus GHRP produces more GH per pulse than either alone, with a side-effect profile most people find tolerable for indefinite use.

Best for

Best when you want a stronger GH pulse profile. The two molecules synergise — more GH per pulse than either alone.

Sermorelin

The oldest GHRH analogue still in widespread use — the first 29 amino acids of natural GHRH, unmodified. Pulses the pituitary in line with the body's natural sleep-onset GH window.

Best for

Best when you want a minimal, single-molecule, sleep-aligned protocol. Lower ceiling, cleaner reasoning.

CJC-1295 / Ipamorelin

GHRH + GHRP synergy is well-documented in short-term human studies going back to the early 2000s — the pulse-amplification effect is real and replicated across multiple research groups. What is limited is long-term safety and body-recomposition outcome data. The 12-week protocols people run are an extrapolation from the acute-pulse pharmacology, not from a body-recomp RCT base. The mechanism is tight; the chronic-use evidence is thinner than the popularity suggests.

Sermorelin

Sermorelin held FDA approval for paediatric GH deficiency from 1997 to 2008, when it was withdrawn from the US market for commercial — not safety or efficacy — reasons. The paediatric trial base is real and was good enough to clear regulatory review. Adult body-recomposition and anti-aging use is off-label and supported by smaller open-label work and the on-label pharmacology rather than a dedicated RCT base in healthy adults. The chronic safety record is reassuring across 25+ years of clinical and grey-market use.